Fennec Pharmaceuticals Inc. (FRX.TO)
CAD 7.05
(0.43%)
CAD 7.05
(0.43%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 38.48 Million USD | 30.43% |
| 2022 | 29.5 Million USD | 344.26% |
| 2021 | 6.64 Million USD | 183.0% |
| 2020 | 2.34 Million USD | 3.35% |
| 2019 | 2.27 Million USD | 38.73% |
| 2018 | 1.63 Million USD | -0.43% |
| 2017 | 1.64 Million USD | 308.96% |
| 2016 | 402 Thousand USD | -14.65% |
| 2015 | 471 Thousand USD | -73.22% |
| 2014 | 1.75 Million USD | -45.15% |
| 2013 | 3.2 Million USD | -56.2% |
| 2012 | 7.32 Million USD | 33.83% |
| 2011 | 5.47 Million USD | -49.89% |
| 2010 | 10.91 Million USD | 2456.67% |
| 2009 | 427 Thousand USD | -85.8% |
| 2008 | 3 Million USD | -1.76% |
| 2007 | 3.06 Million USD | -65.99% |
| 2006 | 8.99 Million USD | 7.28% |
| 2005 | 8.38 Million USD | 0.0% |
| 2003 | 8.73 Million USD | -15.63% |
| 2002 | 10.34 Million USD | 1306.04% |
| 2001 | 736.04 Thousand USD | 15.84% |
| 2000 | 635.4 Thousand USD | 6.53% |
| 1999 | 596.46 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 66.17 Million USD | 71.96% |
| 2024 Q2 | 64.51 Million USD | -2.51% |
| 2023 FY | 38.48 Million USD | 30.43% |
| 2023 Q3 | 29.55 Million USD | 1.35% |
| 2023 Q4 | 38.48 Million USD | 30.2% |
| 2023 Q1 | 29.16 Million USD | -1.18% |
| 2023 Q2 | 29.16 Million USD | 0.01% |
| 2022 Q2 | 7.02 Million USD | 6.07% |
| 2022 Q1 | 6.62 Million USD | -0.26% |
| 2022 Q3 | 27.61 Million USD | 292.98% |
| 2022 Q4 | 29.5 Million USD | 6.85% |
| 2022 FY | 29.5 Million USD | 344.26% |
| 2021 Q2 | 5.83 Million USD | 101.73% |
| 2021 Q4 | 6.64 Million USD | -5.13% |
| 2021 FY | 6.64 Million USD | 183.0% |
| 2021 Q3 | 7 Million USD | 20.0% |
| 2021 Q1 | 2.89 Million USD | 23.22% |
| 2020 Q2 | 3.19 Million USD | 67.28% |
| 2020 Q3 | 2.88 Million USD | -9.56% |
| 2020 Q4 | 2.34 Million USD | -18.65% |
| 2020 FY | 2.34 Million USD | 3.35% |
| 2020 Q1 | 1.9 Million USD | -16.03% |
| 2019 Q1 | 1.45 Million USD | -11.36% |
| 2019 Q3 | 905 Thousand USD | -33.11% |
| 2019 Q4 | 2.27 Million USD | 150.94% |
| 2019 Q2 | 1.35 Million USD | -6.75% |
| 2019 FY | 2.27 Million USD | 38.73% |
| 2018 Q4 | 1.63 Million USD | -21.15% |
| 2018 Q1 | 1.17 Million USD | -28.65% |
| 2018 FY | 1.63 Million USD | -0.43% |
| 2018 Q2 | 847 Thousand USD | -27.79% |
| 2018 Q3 | 2.07 Million USD | 145.1% |
| 2017 Q2 | 580 Thousand USD | 35.83% |
| 2017 FY | 1.64 Million USD | 308.96% |
| 2017 Q4 | 1.64 Million USD | 59.61% |
| 2017 Q3 | 1.03 Million USD | 77.59% |
| 2017 Q1 | 427 Thousand USD | 6.22% |
| 2016 Q4 | 402 Thousand USD | 11.67% |
| 2016 FY | 402 Thousand USD | -14.65% |
| 2016 Q2 | 451 Thousand USD | 30.72% |
| 2016 Q1 | 345 Thousand USD | -26.75% |
| 2016 Q3 | 360 Thousand USD | -20.18% |
| 2015 Q4 | 471 Thousand USD | 9.28% |
| 2015 Q1 | 1.12 Million USD | -36.16% |
| 2015 Q3 | 431 Thousand USD | -43.21% |
| 2015 FY | 471 Thousand USD | -73.22% |
| 2015 Q2 | 759 Thousand USD | -32.41% |
| 2014 FY | 1.75 Million USD | -45.15% |
| 2014 Q4 | 1.75 Million USD | -54.91% |
| 2014 Q3 | 3.9 Million USD | -31.65% |
| 2014 Q2 | 5.7 Million USD | -0.38% |
| 2014 Q1 | 5.72 Million USD | 78.64% |
| 2013 Q2 | 3.45 Million USD | -68.56% |
| 2013 Q1 | 11 Million USD | 50.27% |
| 2013 FY | 3.2 Million USD | -56.2% |
| 2013 Q4 | 3.2 Million USD | -32.72% |
| 2013 Q3 | 4.76 Million USD | 37.81% |
| 2012 Q1 | 2.16 Million USD | -60.48% |
| 2012 FY | 7.32 Million USD | 33.83% |
| 2012 Q3 | 1.64 Million USD | 5.85% |
| 2012 Q2 | 1.55 Million USD | -28.08% |
| 2012 Q4 | 7.32 Million USD | 344.84% |
| 2011 Q1 | 7.92 Million USD | -27.43% |
| 2011 FY | 5.47 Million USD | -49.89% |
| 2011 Q4 | 5.47 Million USD | -44.97% |
| 2011 Q3 | 9.94 Million USD | 32.3% |
| 2011 Q2 | 7.51 Million USD | -5.15% |
| 2010 Q4 | 10.91 Million USD | 118.43% |
| 2010 Q2 | 360.00 USD | -99.92% |
| 2010 Q1 | 430 Thousand USD | 0.7% |
| 2010 FY | 10.91 Million USD | 2456.67% |
| 2010 Q3 | 4.99 Million USD | 1388233.33% |
| 2009 Q4 | 427 Thousand USD | -22.5% |
| 2009 Q2 | 1.29 Million USD | -39.36% |
| 2009 Q3 | 551 Thousand USD | -57.52% |
| 2009 Q1 | 2.13 Million USD | -28.87% |
| 2009 FY | 427 Thousand USD | -85.8% |
| 2008 Q3 | 3.5 Million USD | 16.06% |
| 2008 Q1 | 3.02 Million USD | -1.14% |
| 2008 Q4 | 3 Million USD | -14.18% |
| 2008 Q2 | 3.01 Million USD | -0.23% |
| 2008 FY | 3 Million USD | -1.76% |
| 2007 Q2 | 2.19 Million USD | -19.88% |
| 2007 FY | 3.06 Million USD | -65.99% |
| 2007 Q4 | 3.06 Million USD | 8.16% |
| 2007 Q3 | 2.83 Million USD | 29.11% |
| 2007 Q1 | 2.73 Million USD | -69.6% |
| 2006 FY | 8.99 Million USD | 7.28% |
| 2006 Q4 | 8.99 Million USD | 4.32% |
| 2006 Q3 | 8.62 Million USD | 11.28% |
| 2006 Q2 | 7.75 Million USD | -2.98% |
| 2006 Q1 | 7.98 Million USD | -4.75% |
| 2005 Q4 | 8.38 Million USD | -9.93% |
| 2005 FY | 8.38 Million USD | 0.0% |
| 2005 Q2 | 9.76 Million USD | 9.56% |
| 2005 Q3 | 9.31 Million USD | -4.68% |
| 2005 Q1 | 8.91 Million USD | 0.0% |
| 2004 Q2 | 8.73 Million USD | 1.81% |
| 2004 Q1 | 8.57 Million USD | -6.77% |
| 2004 Q3 | 8.81 Million USD | 0.96% |
| 2003 Q1 | 8.3 Million USD | 2.88% |
| 2003 Q2 | 10.34 Million USD | 24.63% |
| 2003 Q3 | 10.02 Million USD | -3.11% |
| 2003 Q4 | 9.19 Million USD | -8.26% |
| 2003 FY | 8.73 Million USD | -15.63% |
| 2002 FY | 10.34 Million USD | 1306.04% |
| 2002 Q3 | 986.16 Thousand USD | 33.98% |
| 2002 Q1 | 572.34 Thousand USD | 8.6% |
| 2002 Q4 | 8.07 Million USD | 718.46% |
| 2002 Q2 | 736.04 Thousand USD | 28.6% |
| 2001 FY | 736.04 Thousand USD | 15.84% |
| 2001 Q3 | 543.72 Thousand USD | -14.43% |
| 2001 Q2 | 635.4 Thousand USD | 0.0% |
| 2001 Q4 | 527.03 Thousand USD | -3.07% |
| 2000 FY | 635.4 Thousand USD | 6.53% |
| 2000 Q4 | 532.75 Thousand USD | 0.0% |
| 1999 FY | 596.46 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Appili Therapeutics Inc. | 12.41 Million CAD | -209.991% |
| Eupraxia Pharmaceuticals Inc. | 25.54 Million CAD | -50.651% |
| Helix BioPharma Corp. | 1.57 Million CAD | -2337.365% |
| Microbix Biosystems Inc. | 11.02 Million CAD | -248.967% |
| Medicenna Therapeutics Corp. | 13.94 Million CAD | -176.024% |
| Satellos Bioscience Inc. | 3.62 Million CAD | -961.976% |
| Oncolytics Biotech Inc. | 11.25 Million CAD | -241.885% |
| Sernova Corp. | 9.59 Million CAD | -301.218% |